The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shamalov N.A.

Federal Center for Brain and Neurotechnologies

Khasanova D.R.

Kazan State Medical University

Voznyuk I.A.

Pavlov First Saint Petersburg Medical University

Alasheev A.M.

Regional Clinical Hospital No. 1

Khan D.S.

Primorsky Regional Clinical Hospital No. 1

Khalo N.V.

Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after I.S. Berzon

Timchenko L.V.

Research Institute — Regional Clinical Hospital No. 1 named after S.V. Ochapovsky

Bogatyreva M.D.

Stavropol Regional Clinical Hospital

Chuprina S.E.

Regional Clinical Hospital No. 1

Kiseleva T.V.

Federal Center for Brain and Neurotechnology

Marskaya N.A.

Federal Center for Brain and Neurotechnology

Martynov M.Yu.

Federal Center for Brain and Neurotechnology;
Pirogov Russian National Research Medical University (Pirogov University)

Gusev E.I.

Pirogov National Research Medical University

Results of the implementation of reperfusion technologies in ischemic stroke

Authors:

Shamalov N.A., Khasanova D.R., Voznyuk I.A., Alasheev A.M., Khan D.S., Khalo N.V., Timchenko L.V., Bogatyreva M.D., Chuprina S.E., Kiseleva T.V., Marskaya N.A., Martynov M.Yu., Gusev E.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(8‑2): 32‑39

DOI: 10.17116/jnevro202512508232

Read: 751 times

Download PDF (RU)
Contact the author
Table of contents

RESULTS OF THE IMPLEMENTATION OF REPERFUSION TECHNOLOGIES IN ISCHEMIC STROKE
RESULTS OF THE IMPLEMENTATION OF REPERFUSION TECHNOLOGIES IN ISCHEMIC STROKE

To cite this article:

Shamalov NA, Khasanova DR, Voznyuk IA, et al. . Results of the implementation of reperfusion technologies in ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(8‑2):32‑39. (In Russ.)
https://doi.org/10.17116/jnevro202512508232

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Clinical and gene­tic asso­ciations in patients with non-cardioembolic ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):12-19
Biomarkers of athe­rothrombotic and cardioembolic subtypes of acute ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):20-26
Clinical and tomo­graphic comparisons in patients with apha­sia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):27-33
Neuroimaging predictors of hemo­rrhagic transformation of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):34-38
Neurocytoprotection adva­nces in repe­rfusion therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):75-88
Improving the effe­ctiveness of treatment of patients with post-stroke apha­sia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):22-28
Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18
The effe­ctiveness of drug therapy in the reha­bilitation of patients with post-stroke apha­sia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):132-139
Oxidative stress and antioxidant protection in diso­rders of cere­bral circulation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):114-119
Sequential use of botu­linum toxin A and bovhyaluronidase azoximer in the correction of post-stroke spasticity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):80-85
Abstract:

INTRODUCTION

Ischemic stroke (IS) remains a serious medical and social issue due to its high prevalence, mortality, and resulting disability. Reperfusion therapy is an effective method of treating patients with IS.

OBJECTIVE

The aim of this study was to examine the results of implementation of reperfusion technologies for the treatment of IS in the Russian Federation.

MATERIAL AND METHODS

The analysis was based on nationwide data collected from 2015 through the first quarter of 2025. The following indicators were assessed: the proportion of IS patients admitted to stroke units within the first 4.5 hours after symptom onset; the frequency of intravenous thrombolytic therapy (IVT), including the use of telemedicine technologies for IVT administration; the rate of thrombectomy; and the hospital mortality rate from IS. The implementation of telemedicine technologies was evaluated based on the presence of teleconsulted primary stroke units (tele-PSUs) in each region and the proportion of IS patients who received IVT in tele-PSUs.

RESULTS

Over the study period, an increase was observed in the proportion of IS patients admitted within 4.5 hours of symptom onset — from 23% in 2015 to 31% in 2024. The frequency of IVT and thrombectomy procedures increased from 2% and 0.1% in 2015 to 10.2% and 2.8% in the first quarter of 2025, respectively. The rate of IVT performed in tele-PSUs in 2024 was 13.6% of IS patients admitted to tele-PSUs. The ischemic stroke mortality rate decreased from 16.8% in 2015 to 12.6% in the first quarter of 2025.

CONCLUSIONS

Reperfusion therapy technologies for IS are being actively implemented across the country, significantly improving clinical approaches to stroke management. Increasing the number of reperfusion procedures will contribute to improved patient outcomes, reduced mortality, and increase the number of individuals achieving favorable recovery of neurological functions.

Keywords:

ischemic stroke
thrombolytic therapy
IVT
reperfusion therapy
systemic thrombolysis
tele-PSU
thrombectomy

Authors:

Shamalov N.A.

Federal Center for Brain and Neurotechnologies

Khasanova D.R.

Kazan State Medical University

Voznyuk I.A.

Pavlov First Saint Petersburg Medical University

Alasheev A.M.

Regional Clinical Hospital No. 1

Khan D.S.

Primorsky Regional Clinical Hospital No. 1

Khalo N.V.

Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after I.S. Berzon

Timchenko L.V.

Research Institute — Regional Clinical Hospital No. 1 named after S.V. Ochapovsky

Bogatyreva M.D.

Stavropol Regional Clinical Hospital

Chuprina S.E.

Regional Clinical Hospital No. 1

Kiseleva T.V.

Federal Center for Brain and Neurotechnology

Marskaya N.A.

Federal Center for Brain and Neurotechnology

Martynov M.Yu.

Federal Center for Brain and Neurotechnology;
Pirogov Russian National Research Medical University (Pirogov University)

Gusev E.I.

Pirogov National Research Medical University

Received:

23.06.2025

Accepted:

24.06.2025

Close metadata

References:

  1. Skvortsova VI, Stakhovskaya LV, Airiyan NYu. Epidemiology of stroke in the Russian Federation Systemic Hypertension. 2005;(1):10-12. (In Russ.).
  2. GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(10):973-1003. https://doi.org/10.1016/S1474-4422(24)00369-7
  3. Skvortsova VI, Shetova IM, Kakorina EP, et al. Results of implementation of a «Complex of measures to improve medical care for patients with stroke in the Russian Federation» S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(4):5-12. (In Russ.). https://doi.org/10.17116/jnevro2018118415-12
  4. Hacke W, Berg-Dammer E, Zeumer H. Evoked potential monitoring during acute occlusion of the basilar artery and selective local thrombolytic therapy. Arch Psychiatr Nervenkr. 1983;232(6):541-548.  https://doi.org/10.1007/BF00344069
  5. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke. 1976;7(2):135-142.  https://doi.org/10.1161/01.str.7.2.135
  6. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Lancet. 1995;346(8989):1509-1514.
  7. Hommel M, Cornu C, Boutitie F, Boissel JP. Multicenter Acute Stroke Trial-Europe Study Group, Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335(3):145-150.  https://doi.org/10.1056/NEJM199607183350301
  8. Yasaka M, O’Keefe GJ, Chambers BR, et al. Streptokinase in acute stroke: effect on reperfusion and recanalization. Australian Streptokinase Trial Study Group. Neurology. 1998;50(3):626-632.  https://doi.org/10.1212/wnl.50.3.626
  9. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1587. https://doi.org/10.1056/NEJM199512143332401
  10. Hacke W, Kaste M, Bluhmki E, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. https://doi.org/10.1056/NEJMoa0804656
  11. Skvortsova VI, Golukhov GN, Gubskiy LV, et al. Systemic thrombolysis in ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2006;106(12):24-31. (In Russ.).
  12. Skvortsova VI, Golukhov GN, Volynsky YuD, et al. High efficacy of selective intra-arterial thrombolysis in ischemic stroke patients with large-vessel occlusion S.S. Korsakov Journal of Neurology and Psychiatry. 2006;106(12):32-40. (In Russ.).
  13. Pravila provedeniya issledovanij biologicheskikh lekarstvennykh sredstv Evrazijskogo ekonomicheskogo soyuza: Reshenie Soveta Evrazijskoj ekonomicheskoj komissii No. 89 ot 03.11.2016. M., 2016. (In Russ.). Accessed Jan 14, 2025. https://www.garant.ru/products/ipo/prime/doc/71446406
  14. Gusarova VD, Pantyushenko MS, Simonov VM, et al. Physico-Chemicaland Biological Propertiesof Biosimilarand Reference Tissue Plasminogen Activator Products. BIOpreparaty. Profilaktika, diagnostika, lechenie = BIOpreparations. Prevention, Diagnosis, Treatment. 2019;19(1):39-49. (In Russ.). https://doi.org/10.30895/2221-996X-2019-19-1-39-49
  15. Kokorin VA, Markova OA, Gordeev IG, et al. Comparative safety and efficacy study of Russian recombinant tissue plazminogen activator Revelisa® in patients with myocardial infarction. Therapy. 2019;2:42-56. (In Russ.). https://doi.org/10.18565/therapy.2019.2.42-57
  16. Soldatov MA, Klimov LV, Tolmachev AP, et al. Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(12-2):1-8. (In Russ.). https://doi.org/10.17116/jnevro202212212242
  17. Murtazalieva DM, Zakar’yaeva AR, Soshina TD, et al. Experience of using a Russian alteplase product as thrombolytic therapy in patients with ischemic stroke in routine practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(8 vyp. 2):1-5. (In Russ.). https://doi.org/10.17116/jnevro202312308255
  18. Shamalov NA, Khasanova DR, Marchenko SV, et al. Thrombolytic therapy with Revelisa in ischemic stroke: results of the PRIMA international multicenter observational study. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(1):57-66. (In Russ.). https://doi.org/10.14412/2074-2711-2025-1-57-66
  19. Gusev EI, Martynov MY, Nikonov AA, et al; FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset In Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021;20(9):721-728.  https://doi.org/10.1016/S1474-4422(21)00210-6
  20. Haley EC Jr, Thompson JL, Grotta JC, et al; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41(4):707-711.  https://doi.org/10.1161/STROKEAHA.109.572040
  21. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099-1107. https://doi.org/10.1056/NEJMoa1109842
  22. Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14(4):368-376.  https://doi.org/10.1016/S1474-4422(15)70017-7
  23. Campbell BCV, Mitchell PJ, Churilov L, et al; EXTEND-IA TNK Investigators. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018;378(17):1573-1582. https://doi.org/10.1056/NEJMoa1716405
  24. Li S, Pan Y, Wang Z, et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study. Stroke Vasc Neurol. 2022;7(1):47-53.  https://doi.org/10.1136/svn-2021-00097
  25. Bivard A, Zhao H, Churilov L, et al; TASTE-A collaborators. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial. Lancet Neurol. 2022;21(6):520-527.  https://doi.org/10.1016/S1474-4422(22)00171-5
  26. Manosalva A, Siddiqui M, Zafar A, et al; AcT Trial Investigators. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161-169.  https://doi.org/10.1016/S0140-6736(22)01054-6
  27. Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781-788.  https://doi.org/10.1016/S1474-4422(17)30253-3
  28. Kvistad CE, Næss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022;21(6):511-519.  https://doi.org/10.1016/S1474-4422(22)00124-7
  29. Alamowitch S, Turc G, Palaiodimou L, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J. 2023;8(1):8-54.  https://doi.org/10.1177/23969873221150022
  30. Saver JL, Goyal M, Bonafe A, et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285-2295. https://doi.org/10.1056/NEJMoa1415061
  31. Jovin TG, Chamorro A, Cobo E, et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296-2306. https://doi.org/10.1056/NEJMoa1503780
  32. Goyal M, Demchuk AM, Menon BK, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019-1030. https://doi.org/10.1056/NEJMoa1414905
  33. Campbell BC, Mitchell PJ, Kleinig TJ, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009-1018. https://doi.org/10.1056/NEJMoa1414792
  34. Berkhemer OA, Fransen PS, Beumer D, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11-20.  https://doi.org/10.1056/NEJMoa1411587
  35. Albers GW, Marks MP, Kemp S, et al; DEFUSE 3 Investigators. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018;378(8):708-718.  https://doi.org/10.1056/NEJMoa1713973
  36. Nogueira RG, Jadhav AP, Haussen DC, et al; DAWN Trial Investigators. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018;378(1):11-21.  https://doi.org/10.1056/NEJMoa1706442
  37. Skrypnik DV, Anisimov KV, Botsina AY, et al. Endovascular treatment results in patients with large cerebral artery occlusions in a metropolis. Moscow Stroke Registry data over 2019. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(5):9-17. (In Russ.). https://doi.org/10.14412/2074-2711-2020-5-9-17
  38. Shamalov NA. Reperfusion therapy for ischemic stroke in the Russian Federation:Problems and promises. Neurology, Neuropsychiatry, Psychosomatics. 2014;6(2S):15-22. (In Russ.).
  39. Gajurel BP, Nepal G, Jaiswal V, et al. Utilization rates of intravenous thrombolysis for acute ischemic stroke in Asian countries: A systematic review and meta-analysis. Medicine (Baltimore). 2023;102(42):e35560. https://doi.org/10.1097/MD.0000000000035560
  40. Kim J, Olaiya MT, De Silva DA, et al. Global stroke statistics 2023: Availability of reperfusion services around the world. Int J Stroke. 2024;19(3):253-270.  https://doi.org/10.1177/17474930231210448
  41. Emberson J, Lees KR, Lyden P, et al; Stroke Thrombolysis Trialists’ Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929-1935. https://doi.org/10.1016/S0140-6736(14)60584-5
  42. Katzan IL, Hammer MD, Hixson ED, et al; Cleveland Clinic Health System Stroke Quality Improvement Team. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004;61(3):346-350.  https://doi.org/10.1001/archneur.61.3.346
  43. van Wijngaarden JD, Dirks M, Niessen LW, et al. Do centres with well-developed protocols, training and infrastructure have higher rates of thrombolysis for acute ischaemic stroke? QJM. 2011;104(9):785-791.  https://doi.org/10.1093/qjmed/hcr075
  44. van Wijngaarden JD, Dirks M, Huijsman R, et al; Promoting Acute Thrombolysis for Ischaemic Stroke (PRACTISE) Investigators. Hospital rates of thrombolysis for acute ischemic stroke: the influence of organizational culture. Stroke. 2009;40(10):3390-3392. https://doi.org/10.1161/STROKEAHA.109.559492
  45. Boode B, Welzen V, Franke C, et al. Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc Dis. 2007;23(4):294-298.  https://doi.org/10.1159/000098330
  46. Altersberger VL, Sibolt G, Enz LS, et al; TRISP collaborators. Intravenous Thrombolysis 4.5-9 Hours After Stroke Onset: A Cohort Study from the TRISP Collaboration. Ann Neurol. 2023;94(2):309-320.  https://doi.org/10.1002/ana.26669
  47. Al-Janabi OM, Jazayeri SB, Toruno MA, et al. Safety and efficacy of intravenous thrombolytic therapy in the extended window up to 24 hours: A systematic review and meta-analysis. Ann Clin Transl Neurol. 2024;11(12):3310-3319. https://doi.org/10.1002/acn3.52239
  48. Elsherif S, Legere B, Mohamed A, et al. Beyond conventional imaging: A systematic review and meta-analysis assessing the impact of computed tomography perfusion on ischemic stroke outcomes in the late window. Int J Stroke. 2025;20(3):278-288.  https://doi.org/10.1177/17474930241292915
  49. https://cr.minzdrav.gov.ru/preview-cr/814_1  https://cr.minzdrav.gov.ru/preview-cr/814_1
  50. Xiong Y, Campbell BCV, Schwamm LH, et al; TRACE-III Investigators. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy. N Engl J Med. 2024;391(3):203-212.  https://doi.org/10.1056/NEJMoa2402980
  51. Alasheev AM, Prazdnichkova EV, Belkin AA. Experience of providing medical care for patients with stroke in teleconsulted stroke units in the Sverdlovsk region. Manager Zdravookhranenia. 2024;1:85-90. (In Russ.). https://doi.org/10.21045/1811-0185-2024-1-85-90
  52. Turc G, Hadziahmetovic M, Walter S, et al. Comparison of mobile stroke unit with usual care for acute ischemic stroke management: a systematic review and meta-analysis. JAMA Neurol. 2022;79(3):281-290.  https://doi.org/10.1001/jamaneurol.2021.5321
  53. Norrving B, Barrick J, Davalos A, et al. Action Plan for Stroke in Europe 2018-2030. Eur Stroke J. 2018;3(4):309-336.  https://doi.org/10.1177/2396987318808719
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.